Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Income (2021 - 2025)

Amylyx Pharmaceuticals has reported Net Income over the past 5 years, most recently at $111.6 million for Q4 2025.

  • Quarterly results put Net Income at $111.6 million for Q4 2025, down 57.77% from a year ago — trailing twelve months through Dec 2025 was -$158000.0 (down 1228.57% YoY), and the annual figure for FY2025 was -$158000.0, down 1228.57%.
  • Net Income for Q4 2025 was $111.6 million at Amylyx Pharmaceuticals, up from -$34.4 million in the prior quarter.
  • Over the last five years, Net Income for AMLX hit a ceiling of $264.2 million in Q4 2024 and a floor of -$118.8 million in Q1 2024.
  • Median Net Income over the past 5 years was -$25.7 million (2021), compared with a mean of -$1.7 million.
  • Peak annual rise in Net Income hit 2984.78% in 2024, while the deepest fall reached 7652.0% in 2024.
  • Amylyx Pharmaceuticals' Net Income stood at -$28.3 million in 2021, then soared by 650.92% to $156.0 million in 2022, then tumbled by 94.51% to $8.6 million in 2023, then surged by 2984.78% to $264.2 million in 2024, then plummeted by 57.77% to $111.6 million in 2025.
  • The last three reported values for Net Income were $111.6 million (Q4 2025), -$34.4 million (Q3 2025), and -$41.4 million (Q2 2025) per Business Quant data.